

Fig. 5 Activation of MAP kinase signaling pathways in THP-1 cells treated with MBZ. Immunoblot analyses of MAP kinase proteins in THP-1 cells were performed (a, c, and e) and quantified (b, d, and f). Before the treatment with 10 μM MBZ, THP-1 cells were pretreated with the indicated concentrations of MAP kinase inhibitors for 1 h. U0126, SB203580, and, SP600125 were used as specific inhibitors of MEK1/2, p38 MAP kinase, and, JNK1/2, respectively. After 1 h-incubation with MBZ, cell lysates were subjected to immunoblot

analyses using antibodies of anti-Thr202/Tyr204 phosphorylated ERK1/2 (a and b), anti-Thr180/Tyr182 phosphorylated p38 MAP kinase (c and d), and anti-Thr183/Tyr185 phosphorylated JNK1/2 (e and f). The same sample treated with 2 μg/ml LPS was used as a positive control. Data represent the mean ± SD of triplicate determinations. ** $P < 0.01$; *** $P < 0.001$, compared with control (0.1% DMSO). †† $P < 0.01$; ††† $P < 0.001$, compared with MBZ only

The phosphorylation of JNK1/2 treated with LPS was suppressed by the pretreatment with the specific inhibitor SP600125 (data not shown).

Effects of MAP kinase inhibitors on the release of IL-8 and TNFα from THP-1 cells treated with helminthic drugs

To clarify which MAP kinase signaling pathway is mainly involved in the increase of IL-8 and TNFα release, the effects of MAP kinase inhibitors on the release of IL-8 and TNFα from THP-1 cells treated with MBZ were investigated. As shown in Fig. 6, the increased release of IL-8 and TNFα by MBZ treatment from THP-1 cells was significantly suppressed in a dose dependent manner by the pretreatment with U0126, suggesting that an ERK1/2 pathway plays an important role in the release of IL-8 and TNFα by MBZ treatment. A suppressing effect by SP600125 was not observed. In contrast, the increase of IL-8 and TNFα release was enhanced by the pretreatment with SB203580. Therefore, we investigated the effects of MAP kinase inhibitors on the release of IL-8 and TNFα from THP-1 cells treated with other helminthic drugs. As shown in Fig. 7, with ABZ, FBZ, or OBZ treatment, the pretreatment with U0126 remarkably suppressed the increase of IL-8 and TNFα in THP-1 cells and those of SB203580 and SP600125 had no suppressive effects. These

results suggested that an ERK1/2 pathway also plays an important role in the increase of IL-8 and TNFα by ABZ, FBZ, or OBZ treatment as well as MBZ treatment. In contrast, even for the control, the basal IL-8 and TNFα levels in THP-1 cells were significantly suppressed by the pretreatment with U0126 and were increased by the pretreatment with SB203580, suggesting that the basal IL-8 and TNFα levels in THP-1 cells were affected by the MAP kinase inhibitors. In the case of ABZSO and PZQ, the effects of MAP kinase inhibitors on the IL-8 and TNFα levels in THP-1 cells were similar to those of the control (0.1% DMSO).

Discussion

For in vitro studies of the differentiation and activation of immune cells, human monocytic cell lines, THP-1, HL-60, and KG-1 cells are usually employed. In the present study, by the treatment with the helminthic drugs MBZ, IL-8 release from THP-1, HL-60, and KG-1 cells and TNFα release from THP-1 cells was significantly increased compared with the control (Fig. 2a–c, e). In the case of ABZ, FBZ, or OBZ, the release of IL-8 and TNFα from THP-1 cells was also significantly increased compared with the control (Fig. 2a, b). This suggested that MBZ and structurally similar drugs have the ability to stimulate the





Fig. 6 Effects of MAP kinase inhibitors on the IL-8 and TNF α release from THP-1 cells treated with MBZ. Before the treatment with 10 μ M MBZ, THP-1 cells were pretreated with the indicated concentrations of MAP kinase inhibitors for 1 h. After 6 h-incubation with MBZ, the release of IL-8 (a) and TNF α (b) in the supernatant was measured by ELISA. Data represent the mean \pm SD of triplicate determinations. * P < 0.05; ** P < 0.01; *** P < 0.001, compared with control (0.1% DMSO). † P < 0.05; †† P < 0.01; ††† P < 0.001, compared with MBZ only

Fig. 7 Effects of MAP kinase inhibitors on the IL-8 and TNF α release from THP-1 cells treated with helminthic drugs. Before the incubation with 10 μ M of the helminthic drugs, THP-1 cells were pretreated with 10 μ M MAP kinase inhibitors for 1 h. After 6 h-incubation with the helminthic drugs, the release of IL-8 (a) and TNF α (b) in the supernatant was measured by ELISA. Data represent the mean \pm SD of triplicate determinations. *** P < 0.001, compared with control (0.1% DMSO). † P < 0.05; †† P < 0.01; ††† P < 0.001, compared with a helminthic drug only



release of pro-inflammatory cytokines from monocytes, leading to the activation of the inflammatory reaction. In contrast, PZQ, used as a negative control for MBZ, had no effects on the cytokine release in human monocytic cells. This result was supported by the fact that no case of symptomatic hepatic injury has ever been seen so far.

We found that MBZ stimulates the release of pro-inflammatory cytokines and chemokines from human monocytic cells. The activation of inflammatory responses might be one of the mechanisms underlying the immune-mediated liver injury by MBZ. On the other hand, the activation of human monocytic cells by other drugs, such as ximelagatran and troglitazone, has been reported recently, although these drugs have already been withdrawn from the market due to idiosyncratic hepatic injury (Edling et al. 2008, 2009). Ximelagatran increased the release of chemokines from THP-1 cells but the types of released cytokines and the time dependent change of the cytokine release by the drug treatment were different from the case of MBZ (Edling et al. 2008). In addition, troglitazone increased the mRNA expression levels of pro-inflammatory cytokines and chemokines in THP-1 cells (Edling et al. 2009). Therefore, measurement of the release of pro-inflammatory cytokines and chemokines from human monocytic cells may be useful to predict the possibility of adverse reactions to drugs involving immune-mediated hepatic injury.

The activation of MAP kinases such as ERK1/2, p38 MAP kinase, and JNK1/2 is important in mediating many macrophage functions, including the activation of various transcription factors and the production of pro-inflammatory cytokines (Payne et al. 1991; DeFranco et al.

1998). In this study, MBZ activated the ERK1/2 and JNK1/2 pathways in THP-1 cells (Fig. 6). Previous experiments with several MAP kinase inhibitors demonstrated that blocking MAP kinase prevents IL-8 and TNF α release from LPS-stimulated monocytes at the transcription and translation levels (Guha and Mackman 2001). To determine the involvement of MAP kinases in MBZ-induced IL-8 and TNF α release, blocking studies were performed using specific inhibitors of MAP kinases, including U0126, SB203580, and SP600125 (English and Cobb 2002). The release of IL-8 and TNF α increased by MBZ was significantly suppressed by the U0126 pretreatment (Figs. 5, 6). These results suggested that an ERK pathway is mainly involved in IL-8 and TNF α release from THP-1 cells. In addition, the increase of IL-8 and TNF α release from THP-1 cells was enhanced by the pretreatment with SB203580 (Fig. 5). At higher concentrations, the p38 MAP kinase inhibitors have been reported to increase the phosphorylation of ERK1/2 (Ishii et al. 2001; Hirosawa et al. 2009). THP-1 cells also have been reported to show enhanced ERK cascade by SB203580 (Numazawa et al. 2003). Considering these reports, the increase of IL-8 and TNF α release from THP-1 cells by SB203580 would be due to the activation of an ERK pathway.

Elevations of serum aminotransferases have been reported to occur in 9–13% of patients treated with 50–100 mg/kg/day; however, severe hepatic injury of MBZ is very rare. Seitz et al. (1983) and Junge and Mohr (1983) reported MBZ-induced hepatic injury, and liver biopsy of the patient revealed hepatocytic necrosis and portal inflammation with eosinophils during long-term (49–60 days) and high-dose (2–3.5 g/day) therapy with MBZ. Rechallenge was followed by a marked elevation of the aminotransferase levels. Liver biopsy showed hepatocytic necrosis and portal inflammation with eosinophils (Junge and Mohr 1983), suggesting an immune-mediated drug response. Colle et al. (1999) also reported a case of granulomatous (immunoallergic) hepatitis with eosinophilia after the administration of MBZ.

It has been reported that the peak plasma concentrations of MBZ was $0.12 \pm 0.08 \mu\text{M}$ 2 h after a single oral administration of 1000 mg MBZ in 16 healthy volunteers (Corti et al. 2009). Because it is very difficult to predict actual drug concentration in the liver and to extrapolate from an in vitro study to the in vivo condition in humans, it is better to test the drug effects in cell-based assays at a range of concentrations up to at least 30 times the efficacious concentration as reported by O'Brien et al. (2006). Thus, we conducted with up to $10 \mu\text{M}$ of MBZ. However, further study is necessary to clarify whether oral administration of MBZ stimulates the release of pro-inflammatory cytokines and chemokines in vivo.

We obtained ABZSO, an active metabolite of ABZ, which was investigated in this study as a structurally similar drug. ABZSO would be responsible for the systemic biological activity of ABZ, whereas ABZ sulfone is pharmacologically inert (Gottschall et al. 1990). A case report of acute hepatitis caused by ABZ was recently reported by Choi et al. (2008). In evaluating the relation of ABZ and ABZSO to the cytokine release, interestingly, pro-inflammatory cytokine release was found to be increased by treatment with ABZ, but not by ABZSO treatment in human monocytic cells (Figs. 2, 7). These results suggested that ABZ is a causal drug of hepatic injury. However, the activation of THP-1 cells by MBZ was much higher than that by ABZ.

In conclusion, we found that MBZ stimulated human monocytic THP-1 cells resulting in IL-8 and TNF α release. It is suggested that MBZ increases the pro-inflammatory cytokine release from monocytes and macrophages and activates the inflammatory response, which might result in immune-mediated hepatic injury. The findings presented here provide important insight concerning MBZ-induced liver injury.

Acknowledgments We thank Mr. Brent Bell for reviewing the manuscript. This work was supported by Health and Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare of Japan (H20-BIO-G001).

References

- Ammann RW, Eckert J (1996) Cestodes. *Echinococcus*. *Gastroenterol Clin North Am* 25:655–689
- Baggiolini M, Dewald B, Moser B (1994) Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. *Adv Immunol* 55:97–179
- Bagheri H, Simiand E, Montastruc JL, Magnaval JF (2004) Adverse drug reactions to anthelmintics. *Ann Pharmacother* 38:383–388
- Bekhti A, Piroette J (1987) Hepatotoxicity of mebendazole, Relationship with serum concentrations of the drug. *Gastroenterol Clin Biol* 11:701–703
- Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C (1998) Mechanisms of hepatic toxicity. I. TNF-induced liver injury. *Am J Physiol* 275:G387–G392
- Chen K-T, Twu S-J, Chen H-J, Lin R-S (2003) Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. *Am J Public Health* 93:489–492
- Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW (2008) Acute drug-induced hepatitis caused by albendazole. *J Korean Med Sci* 23:903–905. doi: 10.3346/jkms.2008.23.5.903
- Colle I, Naegels S, Hoorens A, Hautekeete M (1999) Granulomatous hepatitis due to mebendazole. *J Clin Gastroenterol* 28:44–45
- Corti N, Heck A, Rentsch K, Zingg W, Jetter A, Stieger B, Pauli-Magnus C (2009) Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. *Eur J Clin Pharmacol* 65:999–1006
- DeFranco AL, Crowley MT, Finn A, Hambleton J, Weinstein SL (1998) The role of tyrosine kinases and map kinases in LPS-induced signaling. *Prog Clin Biol Res* 397:119–136

- Deng X, Luyendyk JP, Ganey PE, Roth RA (2009) Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. *Pharmacol Rev* 61:262–282. doi:10.1124/pr.109.001727
- Edling Y, Sivertsson L, Andersson TB, Porsmyr-Palmertz M, Ingelman-Sundberg M (2008) Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. *Toxicol In Vitro* 22:1588–1594. doi:10.1016/j.tiv.2008.06.011
- Edling Y, Sivertsson LK, Butura A, Ingelman-Sundberg M, Ek M (2009) Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. *Toxicol In Vitro* 23:1387–1395. doi:10.1016/j.tiv.2009.07.026
- English JM, Cobb MH (2002) Pharmacological inhibitors of MAPK pathways. *Trends Pharmacol Sci* 23:40–45
- Ganey PE, Luyendyk JP, Maddox JF, Roth RA (2004) Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. *Chem Biol Interact* 150:35–51. doi:10.1016/j.cbi.2004.09.002
- Gottschall DW, Theodorides VJ, Wang R (1990) The metabolism of benzimidazole anthelmintics. *Parasitol Today* 6:115–124
- Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. *Cell Signal* 13:85–94
- Hirosawa M, Nakahara M, Otosaka R, Imoto A, Okazaki T, Takahashi S (2009) The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. *Leuk Res* 33:693–699. doi:10.1016/j.leukres.2008.09.028
- Holt MP, Ju C (2006) Mechanisms of drug-induced liver injury. *AAPS J* 8:E48–E54. doi:10.1208/aapsj080106
- Ishii Y, Sakai S, Honma Y (2001) Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells. *Leuk Res* 25:813–820
- Jaeschke H (2005) Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. *Expert Opin Drug Metab Toxicol* 1:389–397. doi:10.1517/17425255.1.3.389
- Junge U, Mohr W (1983) Mebendazole-hepatitis. *Z Gastroenterol* 21:736–738
- Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680–685
- Leonard EJ, Yoshimura T, Tanaka S, Raffeld M (1991) Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. *J Invest Dermatol* 96:690–694
- Numazawa S, Watabe M, Nishimura S, Kurosawa M, Izuno M, Yoshida T (2003) Regulation of ERK-mediated signal transduction by p38 MAP kinase in human monocytic THP-1 cells. *J Biochem* 133:599–605
- O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. *Arch Toxicol* 80:580–604
- Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW (1991) Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). *EMBO J* 10:885–892
- Roth RA, Luyendyk JP, Maddox JF, Ganey PE (2003) Inflammation and drug idiosyncrasy—is there a connection? *J Pharmacol Exp Ther* 307:1–8. doi:10.1124/jpet.102.041624
- Seitz R, Schwerk W, Arnold R (1983) Hepatocellular drug reactions caused by mebendazole therapy in cystic echinococcosis. *Z Gastroenterol* 21:324–329
- Tafazoli S, Spehar DD, O'Brien PJ (2005) Oxidative stress mediated idiosyncratic drug toxicity. *Drug Metab Rev* 37:311–325. doi:10.1081/DMR-55227



ELSEVIER

Contents lists available at ScienceDirect

Biochemical Pharmacology

journal homepage: www.elsevier.com/locate/biochempharm

Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2)[☆]

Taiga Maruichi, Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi^{*}

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

ARTICLE INFO

Article history:

Received 21 July 2009

Accepted 19 August 2009

Keywords:

Carboxylesterase

Gene regulation

Nuclear factor-erythroid 2 related factor 2

ABSTRACT

Human carboxylesterase (CES) 1A, which is predominantly expressed in liver and lung, plays an important role in the hydrolysis of endogenous compounds and xenobiotics. CES1A is reported to be induced in human hepatocytes by butylated hydroxyanisole, ticlopidine and diclofenac, and the induction is assumed to be caused by oxidative stress. However, the molecular mechanism remains to be determined. In this study, we sought to investigate whether CES1A is regulated by nuclear factor-erythroid 2 related factor 2 (Nrf2), which is a transcriptional factor activated by oxidative stress, and clarify the molecular mechanism. Real-time reverse transcription-PCR assays revealed that CES1A1 mRNA was significantly induced by *tert*-butylhydroquinone (tBHQ) and sulforaphane (SFN), which are representative activators of Nrf2 in HepG2, Caco-2 and HeLa cells. The induction was completely suppressed with small interfering RNA for Nrf2. In HepG2 cells, the CES1A protein level and imidapril hydrolase activity, which is specifically catalyzed by CES1A, were also significantly induced by tBHQ and SFN. Luciferase assays revealed that the antioxidant response element (ARE) at –2025 in the *CES1A1* gene was responsible for the transactivation by Nrf2. In addition, electrophoretic mobility shift assays and chromatin immunoprecipitation assays revealed that Nrf2 binds to the ARE in the *CES1A1* gene. These findings clearly demonstrated that human CES1A1 is induced by Nrf2. This is the first study to demonstrate the molecular mechanism of the inducible regulation of human CES1A1.

© 2009 Elsevier Inc. All rights reserved.

1. Introduction

Human carboxylesterase (CES) is a member of serine hydrolase superfamily and involved in the hydrolysis of endogenous compounds and xenobiotics. In human, the CES1A and CES2 families play important roles in drug metabolism. The CES1A mainly hydrolyzes substrates with a small alcohol group and large acyl group, such as imidapril [1] and oseltamivir [2]. In contrast, the CES2 prefers substrates with a large alcohol group and small acyl group, such as CPT-11 [3] and heroin [4]. Since CES1A has been reported to play roles as triglyceride hydrolase (TGH) [5], acyl coenzyme A:cholesterol acyltransferase (ACAT) [6] and cholesteryl ester hydrolase (CEH) [7], it seems probable that CES1A is important for the lipid metabolism as well as the drug metabolism. CES1A is predominantly expressed in liver and lung, whereas CES2 is expressed in colon and liver [8]. Human CES1A is classified into two isoforms, CES1A1 and CES1A2, with high homology at the mRNA level (99.3%). It has been accepted that the *CES1A2* gene is

inverted and duplicated with the *CES1A1* gene [9]. However, we recently demonstrated that the *CES1A2* gene is a variant of the *CES1A3* pseudogene [10]. The sequence identity in the 5'-flanking region between the *CES1A1* and *CES1A2* genes is approximately 90% and the sequences downstream intron 1 of them are identical. Since only the N-terminal signal peptide sequences in exon 1 of CES1A1 and CES1A2 are different, mature proteins produced from both mRNA are identical. Our previous study revealed that the levels of CES1A1 mRNA transcribed from the *CES1A1* gene were substantially higher in liver than those of CES1A2 mRNA transcribed from the *CES1A2* gene [10]. Therefore, it is plausible that the level of CES1A1 mRNA rather than that of CES1A2 mRNA affects the level of mature protein and enzyme activity.

Cells are protected against oxidative stress by increasing the transcription of a group of genes coding antioxidant proteins and phase II enzymes, such as NAD(P)H:quinone oxidoreductase1 (NQO1) [11], heme oxygenase1 (HO-1) [12], and UDP-glucuronosyltransferase (UGT) 1A1 [13]. The most important regulator of the up-regulation is the transcription factor nuclear factor-erythroid 2 (NF-E2) related factor 2 (Nrf2). Nrf2 is a member of the cap'n'collar (CNC) family of transcriptional factors and contains a C-terminal basic leucine zipper structure that facilitates dimerization and DNA binding [14]. Nrf2 is highly expressed in detoxification tissues such as liver and kidney, and tissues that are exposed to the

[☆] This study was supported by a Grant-in-Aid for Encouragement of Young Scientists of the Ministry of Education, Science, Sports and Culture #21790148.

^{*} Corresponding author. Tel.: +81 76 234 4407; fax: +81 76 234 4407.

E-mail address: tyokoi@kenroku.kanazawa-u.ac.jp (T. Yokoi).

external environment, such as skin, lung and gastrointestinal tract [15]. In the absence of cellular stress, Nrf2 is localized in cytosol by binding with Kelch-like erythroid cell-derived protein with CNC homology (ECH)-associated protein 1 (Keap1), which acts as a substrate adopter for Cullin-dependent E3 ubiquitin ligase complex. Under the condition of oxidative stress, Nrf2 is released from Keap1 and translocates into the nucleus. After heterodimerization with small Maf protein, Nrf2 stimulates the transcription of the downstream genes by binding to antioxidant response element (ARE), a *cis*-acting enhancer with a consensus sequence defined as 5'-TMAAnRTGABnnnGCAnnnnn-3', in which the core nucleotide is underlined [16,17]. *tert*-Butylhydroquinone (tBHQ) and sulforaphane (SFN) are known to be representative activators of Nrf2 [18].

There are few reports of the regulatory mechanism of human CES1A. Hosokawa et al. [19] demonstrated that Sp1 and C/EBP are involved in the basal expression of CES1A1. In addition, Nishimura et al. [20] reported that, in human hepatocytes, CES1A mRNA was not induced by rifampicin and omeprazole, which are potent ligands of pregnane X receptor and aryl hydrocarbon receptor (AhR), respectively. Thus, the inducible regulation of CES1A has not been reported until now. Recently, Takakusa et al. [21] reported that CES1A was induced by butylated hydroxyanisole, ticlopidine and diclofenac in human hepatocytes, and that the induction would be stimulated by oxidative stress. As described above, it is well known that Nrf2 is involved in the induction by oxidative stress. In addition, a computer-assisted homology search revealed putative AREs within -3200 bp of the CES1A1 gene. Thus, it is plausible that Nrf2 is involved in the transcriptional regulation of CES1A. These lines of evidence prompted us to investigate whether the human CES1A1 gene is regulated by Nrf2.

2. Materials and methods

2.1. Chemicals and reagents

tBHQ was purchased from Wako Pure Chemical Industries (Osaka, Japan). L-SFN was purchased from Alexis (San Diego, CA). Imidapril and imidaprilat were kindly supplied by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan). Anti-human Nrf2 antibodies (C-20 and H-300), which recognize the C- and N-terminus of Nrf2 protein, respectively, were from Santa Cruz Biotechnology (Santa Cruz, CA). Stealth Select RNAi for Nrf2 (HSS107130) (5'-aaucacugaggccaaguaguguguc-3') and Stealth RNAi negative control, Medium GC Duplex #2 were from Invitrogen (Carlsbad, CA). All primers and oligonucleotides were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). All other reagents were of the highest grade commercially available.

2.2. Cells and culture conditions

The human hepatoma cell line HepG2 and human colon carcinoma cell line Caco-2 were obtained from American Type Culture Collection (Manassas, VA). Human adenocarcinoma of the cervix of uterus cell line HeLa was obtained from RIKEN BioResource Center (Ibaraki, Japan). HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS) (Invitrogen). HepG2 and Caco-2 cells were cultured in DMEM supplemented with 10% FBS and 0.1 mM nonessential amino acids (Invitrogen). The cells were maintained at 37 °C under an atmosphere of 5% CO₂.

2.3. Real-time reverse transcription (RT)-polymerase chain reaction (PCR) analysis

Total RNA was extracted using RNAiso (Takara Bio, Shiga, Japan) and cDNA was synthesized from total RNA using ReverTra Ace

Table 1

Sequences of oligonucleotide used in the present study.

Oligonucleotide	Sequence
For real-time RT-PCR	
CES1A1 S ^a	5'-atgtggctccgtgctt-3'
CES1A1 AS ^a	5'-tcttcacaaagctccatggt-3'
CES2 S ^b	5'-aacctgtctgcttgaccaagt-3'
CES2 AS ^b	5'-acatcagcagcgttaacatttctg-3'
HO-1 S ^c	5'-atagagcgaacaaagcaga-3'
HO-1 AS ^c	5'-tagagctgtttgaactgg-3'
GAPDH S ^d	5'-ccaggctgctcttaactc-3'
GAPDH AS ^d	5'-gctccccctgcaaatga-3'
For SOE-PCR	
pGL3 S	5'-tagcaaaataggctgctccc-3'
pGL3 AS	5'-tcgatatgtgcatctgtaaaa-3'
ARE2 mt-A	5'-atctaaggcaaatTTCTGTCAgctcatt-3'
ARE2 mt-B	5'-aatgagcTGACAAGAAatttgccttagat-3'
ARE3 mt-A	5'-acagcaactcaatTTAAAGTCAGaaccag-3'
ARE3 mt-B	5'-ctggctTGACTTTAAcattgagttgctg-3'
ARE4 mt-A	5'-ccggtgagattaatTTGTCTCAgactct-3'
ARE4 mt-B	5'-aagatcGTAGACAAAattaatctcaggg-3'
For ChIP assays	
CES1A1 -2178 S	5'-gaccttaggcaatccctcct-3'
CES1A1 -1855 AS	5'-tggctgtaattctgtcagttctt-3'
CES1A1 -1274 S	5'-tcttggtgacaagctttgtg-3'
CES1A1 -956 AS	5'-cacaaggaagctcactcaag-3'
CES1A1 -958 S	5'-gtgtccccagcagctgtgaa-3'
CES1A1 -666 AS	5'-aaaatgaactccgctcccc-3'
For electrophoresis mobility shift assays	
cARE ^e	5'-gatctttatgtgagctcatggtt-3'
CES1A1 ARE4	5'-atattaagatGTAGACAGCattaatctc-3'
CES1A1 ARE4mt	5'-atattaagatGTAGACAAAattaatctc-3'
CES1A1 ARE6	5'-taggggaattGCTGGGTCAatggaaactc-3'
CES1A1 ARE6mt	5'-taggggaattTTGGGTCAatggaaactc-3'

The core ARE is indicated by capital letters and mutated nucleotides are underlined.

^a From Fukumi et al. [10].

^b From Sanghani et al. [23].

^c From Nakamura et al. [24].

^d From Tsuchiya et al. [22].

^e From Balogun et al. [12].

(TOYOBO, Osaka, Japan) according to the manufacturer's protocol. Human GAPDH mRNA was quantified by real-time RT-PCR using the Smart Cycler (Cepheid, Sunnyvale, CA) as described previously [22]. CES1A1, CES2 and HO-1 mRNA levels were quantified under the same condition. PCR was performed with the following primer sets: CES1A1, CES1A1 S and CES1A1 AS; CES2, CES2 S and CES2 AS; HO-1, HO-1 S and HO-1 AS (Table 1).

2.4. Immunoblot analysis

The expression of CES1A protein was measured by SDS-polyacrylamide gel electrophoresis and immunoblot analysis according to Laemmli [25]. For the preparation of cell homogenates, HepG2 cells were suspended in TGE buffer (10 mM Tris-HCl (pH 7.4), 20% glycerol, 1 mM EDTA) and disrupted by freeze-thawing three times. The protein concentrations were determined according to Bradford [26]. Cell homogenates (30 µg) were separated on 7.5% polyacrylamide gels and electrotransferred onto polyvinylidene difluoride membrane, Immobilon-P (Millipore, Billerica, MA). The membranes were probed with polyclonal rabbit anti-human CES1A (Abcam, Cambridge, MA), and IRDye680-labeled anti-rabbit IgG and an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE) were used for detection. The relative expression level was quantified using ImageQuant TL Image Analysis software (GE Healthcare, Buckinghamshire, UK).

2.5. Imidapril hydrolase activity

The imidapril hydrolase activity was determined according to the method described previously with a slight modification [27]. A

typical standard reaction mixture (total volume, 0.2 ml) contained HepG2 cell homogenates (1 mg/ml), 100 mM Tris-HCl buffer (pH 7.4) and 100 μ M imidapril. The final concentration of the organic solvent in the reaction mixture was <1.0%. The reaction was initiated by the addition of imidapril after 2 min of preincubation at 37 °C. After 30 min of incubation, the reaction was terminated by adding 100 μ l of ice-cold acetonitrile. After the removal of protein by centrifugation at 9500 \times g for 5 min, a 10 μ l portion of the supernatant was subjected to liquid chromatography-tandem mass spectrometry with an Inertsil ODS-3 analytical column (2.1 mm \times 100 mm; GL Science, Tokyo, Japan). The mobile phase consisted of acetonitrile/10 mM ammonium formate (20:80). The mass/charge (*m/z*) ion transitions were recorded in the multiple reaction monitoring mode: *m/z* 378.2 and 206.3 for imidapril.

2.6. Construction of reporter plasmid

A pGL3 plasmid containing two copies of the consensus ARE (2 \times cARE) in the human *NQO-1* gene (5'-gatcagtcacagtgcagcagaactc-3'), which was previously constructed in our laboratory [24], was used as a positive control. The PCR fragments of the 5'-flanking region (-3207 to -1 bp) in the *CES1A1* gene amplified using genomic DNA samples were cloned into the pGL3-basic vector (Promega, Madison, MI) after treatment with Klenow Fragment (Takara) and digestion with *Xho* I. This plasmid (-3207 to -1 bp) was used for construction of the other reporter plasmids (-1531 to -1, and -833 to -1 bp) by digestion and subcloning. Throughout this article, base A in the initiation codon ATG is denoted +1 and the base before A is numbered -1. Three reporter plasmids containing ARE(s), the -3041 to -2891 bp plasmid that contained ARE1, the -2365 to -1989 bp plasmid that contained ARE2, ARE3 and ARE4, and the -1310 to -1170 bp plasmid that contained ARE5 and ARE6 were constructed by PCR and subcloning. The plasmids mutated at the AREs (ARE2 mt, ARE3 mt and ARE4 mt) were constructed by splicing with overlap extension (SOE)-PCR [28]. The regions around the nucleotides to be mutated were amplified using primer pairs pGL3 S and mt-A (PCR 1), or mt-B and pGL3 AS (PCR 2) (Table 1). The following SOE-PCR was performed with the primer pair pGL3 S and pGL3 AS, combining the PCR products 1 and 2. The SOE-PCR products were digested with the appropriate restriction enzymes and subcloned into the pGL3-tk vector. The nucleotide sequences were confirmed by DNA sequence analysis (Long-Read Tower DNA sequencer; GE Healthcare).

2.7. Transfection and luciferase assay

For siRNA transfection, HepG2, Caco-2 and HeLa cells were transfected with 30 pmol siRNA by using lipofectamine RNAiMAX (Invitrogen). After incubation for 24 h, the cells were treated with 80 μ M tBHQ, 10 μ M SFN or 0.1% dimethyl sulfoxide (DMSO) for 24 h. For the luciferase assays, HepG2 cells were seeded into 24-well plates at 1×10^5 cells/well. Transfection was performed using Tfx-20 reagent (Promega). The transfection mixtures consisted of 200 ng of pGL3 plasmid, 10 ng of phRL-TK plasmid (Promega), and 100 ng of human Nrf2 expression plasmid [24] or pTARGET empty plasmid as a control. The cells were harvested 48 h after transfection and lysed to measure the luciferase activity using a Dual Luciferase Reporter Assay System (Promega). The relative luciferase activities were normalized with the *Renilla* luciferase activities.

2.8. Electrophoretic mobility shift assay (EMSA)

Double-stranded oligonucleotides were labeled with [γ -³²P]ATP using T4 polynucleotide kinase (TOYOBO) and purified by Microspin G-50 columns (GE Healthcare). The oligonucleotide

sequences are shown in Table 1. The labeled probe (40 fmol, ~20,000 cpm) was applied to each binding reaction in 25 mM HEPES-KOH (pH 7.9), 0.5 mM EDTA (pH 8.0), 10% glycerol, 50 mM KCl, 0.5 mM dithiothreitol, 0.5 mM (*p*-amidinophenyl)methanesulfonyl fluoride, 1 μ g of poly(dI-dC), 5 μ g of salmon sperm DNA, and 8 μ g of the nuclear extracts from 0.1% DMSO- or 10 μ M SFN-treated HepG2 cells prepared using NE-PER Nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL) with a final reaction volume of 15 μ l. To determine the specificity of the binding to the oligonucleotides, competition experiments were conducted by co-incubation with 5-, 25-, and 50-fold excesses of unlabeled competitors. For supershift experiments, 2 μ g of anti-Nrf2 antibodies (C-20 and H-300) or normal rabbit IgG were preincubated with the nuclear protein on ice for 30 min. The reactions were incubated on ice for 15 min and then loaded on 4% acrylamide gel in 0.5 \times Tris-borate EDTA buffer. The gels were dried and exposed to film for 24 h. The DNA-protein complexes were detected with a Fuji Bio-Imaging Analyzer BAS 1800 (Fuji Film, Tokyo, Japan).

2.9. Chromatin immunoprecipitation (ChIP) assay

When HepG2 cells reached 60% confluence in 60-mm dishes, they were treated with 0.1% DMSO or 10 μ M SFN. After 24 h incubation, ChIP assays were performed using a ChIP assay kit (Upstate, Lake Placid, NY) according to the manufacturer's protocol. Rabbit anti-Nrf2 antibodies (C-20 and H-300) and normal rabbit IgG were used for immunoprecipitation of the protein-DNA complexes. PCR was performed with the following primer sets: region 1, *CES1A1* -2178 S and *CES1A1* -1855 AS; region 2, *CES1A1* -1274 S and *CES1A1* -956 AS; region 3, *CES1A1* -956 S and *CES1A1* -666 AS (Table 1). The PCR conditions were as follows: after initial denaturation at 94 °C for 3 min, the amplification was performed by denaturation at 94 °C for 25 s, annealing at 58 °C (region 1), 54 °C (region 2) or 60 °C (region 3) for 25 s, and extension at 72 °C for 30 s for 30 cycle. The PCR products were electrophoresed on a 2% agarose gel and visualized by ethidium bromide.

2.10. Statistical analysis

Data are expressed as mean \pm SD. Statistical significance between two groups was determined by two-tailed Student's *t*-test. Statistical significance between multiple groups was determined by ANOVA followed by Dunnett or Tukey test. A value of *P* < 0.05 was considered statistically significant.

3. Results

3.1. Induction of *CES1A* in cultured cells

The effects of tBHQ and SFN on the expression of *CES1A1* mRNA in HepG2, Caco-2 and HeLa cells were examined (Fig. 1). By treatment with 80 μ M tBHQ and 10 μ M SFN, the expression of *CES1A1* mRNA was significantly increased in HepG2 (2.6- and 3.4-fold, respectively), Caco-2 (3.4- and 4.4-fold) and HeLa cells (3.4- and 3.0-fold). Under the same condition, the level of HO-1 mRNA, which is already known to be induced by Nrf2, was also significantly induced in all cell lines. In contrast, the level of *CES2* mRNA was not changed in any of cell lines. The *CES1A* protein expression and enzyme activity were measured to examine whether they were increased by the induction of *CES1A1* mRNA expression by tBHQ and SFN in HepG2 cells. Immunoblot analysis revealed that the expression of *CES1A* protein was clearly increased up to 1.73- and 2.12-fold in HepG2 cells by tBHQ and SFN, respectively (Fig. 1B). In Caco-2 and HeLa cells, it was difficult to detect *CES1A* protein by immunoblot analysis due to the




Fig. 1. (A) Effects of tBHQ and SFN on the CES1A1, CES2 and HO-1 mRNA expression in HepG2, Caco-2, and HeLa cells. The cells were treated with 80 μM tBHQ, 10 μM SFN or DMSO vehicle (0.1%) for 24 h. The expressions of CES1A1, CES2 and HO-1 mRNA were determined by real-time RT-PCR and normalized with the GAPDH mRNA levels. Effects of tBHQ and SFN on the expression of CES1A protein (B) and the imidapril hydrolase activity (C) in HepG2 cells. The cells were treated with 80 μM tBHQ, 10 μM SFN or DMSO vehicle (0.1%) for 24 h. The expression of CES1A protein was determined by immunoblot analysis. Each column represents the mean ± SD of three independent experiments. * $P < 0.05$; ** $P < 0.01$ compared with control (vehicle).

low expression level. Imidapril hydrolase activity, which is specifically catalyzed by CES1A, was also significantly increased in HepG2 cells by tBHQ and SFN (from 3.4 ± 0.23 to 4.13 ± 0.23 and 5.31 ± 0.15 pmol/min/mg protein, respectively) (Fig. 1C). These results indicate that the induction of CES1A1 mRNA expression by tBHQ and SFN led to increases in CES1A protein expression and enzyme activity.

3.2. Effect of Nrf2 knockdown on the induction of CES1A1 by tBHQ and SFN

To investigate whether Nrf2 is responsible for the induction of CES1A1 by tBHQ and SFN, the endogenous Nrf2 was knocked down in HepG2, Caco-2 and HeLa cells (Fig. 2). It was confirmed that the Nrf2 mRNA expression was decreased 79%, 82%, and 88% by siRNA-Nrf2 transfection in HepG2, Caco-2, and HeLa cells, respectively. In all cell lines, tBHQ and SFN mediated induction of CES1A1 mRNA was completely suppressed by the knockdown of Nrf2. In HepG2 and Caco-2 cells, the basal expression level of CES1A1 mRNA was not changed by siRNA-Nrf2 transfection, whereas it was significantly decreased in HeLa cells. These results suggested that Nrf2 plays a critical role in the induction of CES1A1 by tBHQ and SFN.

3.3. Identification of Nrf2 binding site in the 5'-flanking region of the CES1A1 gene

A computer-assisted homology search identified six putative AREs within -3200 bp of the CES1A1 gene (Fig. 3). These AREs at -2971, -2323, -2203, -2025, -1283, and -1218 bp were termed

ARE1, ARE2, ARE3, ARE4, ARE5 and ARE6, respectively. To investigate whether AREs in the CES1A1 gene were functional in Nrf2-dependent transactivation, luciferase assays were performed using reporter plasmids containing the 5'-flanking region of the CES1A1 gene (-3207 to -1, -1531 to -1, and -833 to -1 bp) in HepG2 cells (Fig. 4A). The transcriptional activity of 2× cARE used as positive control was increased up to 2.2-fold by the overexpression of Nrf2. Unexpectedly, the overexpression of Nrf2 did not activate the transcriptional activities of any plasmids. Then, we constructed three reporter plasmids containing ARE-neighboring regions and luciferase assays were performed (Fig. 4B). The transcriptional activities of the -2365 to -1989 bp plasmid that contained ARE2, ARE3 and ARE4 were increased up to 2.0-fold by the overexpression of Nrf2. In contrast, Nrf2 did not activate the transcriptional activities of the -3041 to -2891 bp plasmid that contained ARE1 and the -1310 to -1170 bp plasmid that contained ARE5 and ARE6. To further confirm the functional ARE, a mutation was introduced into each ARE of the -2365 to -1989 bp plasmid. The Nrf2-dependent transcriptional activation with the -2365 to -1989 bp plasmid was completely abolished by introducing the mutation in ARE4 (Fig. 4C). These results suggest that the ARE4 works as a functional Nrf2 response element in the CES1A1 gene.

3.4. Nrf2 directly binds to the ARE at -2025 of the CES1A1 gene

To examine whether Nrf2 directly binds to ARE4, EMSA was performed using the nuclear extract prepared from DMSO- or SFN-treated HepG2 cell and 32 P-labeled ARE4 as a probe (Fig. 5). When




Fig. 2. Effect of Nrf2 knockdown on CES1A1 mRNA induction in HepG2, Caco-2 and HeLa cells. The expression of CES1A1 mRNA was determined by real-time RT-PCR. After 24 h transfection with siRNA, the cells were treated with 80 μM tBHQ, 10 μM SFN or DMSO vehicle (0.1%) for 24 h. To normalize RNA loading and PCR variations, the CES1A1 mRNA levels were corrected with the GAPDH mRNA levels. Each column represents the mean ± SD of three independent experiments. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ compared with control (vehicle).

the probe was incubated with the nuclear extracts from the SFN-treated HepG2 cells, the shifted band was clearly observed. The band density was diminished with both anti-Nrf2 antibodies (C-20 and H-300), although the supershifted band was observed only with the anti-Nrf2 antibody (C-20). These results indicate that the shifted band contained Nrf2 complexes. Moreover, the shifted




Fig. 3. Schematic diagram of putative AREs in the 5'-flanking region of the human CES1A1 gene. Numbers indicate the nucleotide position when the A in the initiation codon ATG is denoted +1 and the base before A is numbered -1. The core ARE sequence is indicated by an arrow. The nucleotides that are consistent with the consensus ARE are shown with capital letters.

band was competed out by excess amounts of unlabeled cARE or ARE4, but not by the mutant ARE, ARE4 mt. These results suggested that Nrf2 binds to the ARE located at -2025 in the 5'-flanking region of the CES1A1 gene.

To further examine whether Nrf2 binds to ARE4 in intact cells, ChIP assays were performed using DMSO- or SFN-treated HepG2 cells (Fig. 6). PCR was performed with primers designed to amplify the -2178 to -1855 bp (region 1) containing ARE4, the -1274 to -956 bp (region 2) containing ARE6 and the -958 to -666 bp (region 3) containing no AREs. Normal rabbit IgG was used as a negative control of immunoprecipitation for ChIP assays. As shown in Fig. 6, the immunoprecipitants of SFN-treated HepG2 cells obtained with anti-Nrf2 antibody (C-20) generated a distinct PCR product for region 1, but those obtained with anti-Nrf2 antibody (H-300) or normal rabbit IgG did not. Using primer sets for region 2 and region 3, no PCR products were obtained with any antibodies. These results suggest that Nrf2 binds to the ARE located at -2025 in the 5'-flanking region of the CES1A1 gene in intact cells.

4. Discussion

In this study, we demonstrated that human CES1A1 is induced by Nrf2. The human CES1A1 gene and CES1A3 pseudogene are inverted and duplicated genes. Our recent study demonstrated that the CES1A2 gene is a variant of the CES1A3 pseudogene [10]. In the present study, we demonstrated that the ARE4 in the CES1A1 gene was the key element of Nrf2-mediated induction, but the sequence of the region corresponding to ARE4 in the CES1A1 gene exists in the CES1A2 gene. Therefore, it is conceivable that CES1A2 mRNA derived from the CES1A2 gene is also induced by Nrf2. The copy numbers of the CES1A2 gene and CES1A3 pseudogene were investigated for HepG2, Caco-2 and HeLa cells according to Fukami et al. [10] (data not shown). HepG2 and Caco-2 cells had two copies of the CES1A3 gene, but HeLa cells had one copy each of the CES1A3 and CES1A2 genes. However, in HeLa cells, CES1A2 mRNA was not detected (data not shown), thus the induction of CES1A2 by Nrf2 could not be further investigated. Since the expression of CES1A2 mRNA is much lower than that of CES1A1 mRNA in human liver [10], the Nrf2-mediated induction of CES1A2 would have a minor effect on the CES1A enzyme activity.

NQO1, HO-1, and UGT1A1 are well known to be induced by tBHQ and SFN via Nrf2 [11–13]. Recently, these inductions have attracted attention as biomarkers of the electrophilic stress caused by the formation of reactive metabolites because they serve as a cellular defense against electrophiles and oxidative stress products [29]. It is plausible that CES1A1 is also a possible biomarker of




Fig. 4. Relative promoter activity of constructs containing putative ARE(s) in the 5'-flanking region of the *CES1A1* gene and the effect of the overexpression of Nrf2 in HepG2 cells. After 48 h transfection, the cells were harvested and assayed for the luciferase activities according to the manufacturer's protocol. The relative luciferase activities were normalized with the *Renilla* luciferase activities. The right part of the figure shows the fold induction of the transcriptional activity by the overexpression of Nrf2. Each column represents the mean \pm SD of three independent experiments. 2xcARE indicates the plasmid containing two copies of the consensus ARE in the human NQO-1 gene. ARE2 mt, ARE3 mt, ARE4 mt indicate the plasmids mutated at the ARE2, ARE3, and ARE4, respectively. Control, pTARGET empty plasmid. * $P < 0.01$ and *** $P < 0.001$.

electrophilic stress because it was demonstrated in this study that *CES1A1* is induced by Nrf2. tBHQ and SFN are also known as ligands of AhR [30,31]. NQO1, HO-1, and UGT1A1 are induced by AhR as well as by Nrf2 [32–34]. In the present study, *CES1A1* induction by tBHQ and SFN was completely suppressed by knockdown of Nrf2. In addition, it was reported that *CES1A* mRNA is not induced by omeprazole, a potent ligand of AhR, in human hepatocytes [20]. These results indicate that only Nrf2 but not AhR would be involved in the *CES1A1* induction by tBHQ and SFN. Interestingly, in HeLa cells, the basal expression level of *CES1A1* mRNA was significantly decreased by the knockdown of Nrf2. This result indicates that Nrf2 regulates the basal expression of *CES1A1* in HeLa cells. Similarly, it was reported that the basal expression level of carboxylesterase in lung and small intestine is decreased in Nrf2 knockout mice [35,36]. In addition to Sp1 and C/EBP [19], Nrf2 might also regulate the basal expression level of *CES1A1*.

Generally, the genes induced by Nrf2 are involved in detoxification [18]. Because *CES1A* expression was induced by Nrf2, it was conceivable that *CES1A* is also involved in detoxification. It was reported that carboxylesterase in human lung microsomes, in which *CES1A* is highly expressed, is involved in the detoxification of vinyl carbamate [37]. To our knowledge, this is the only report suggesting the involvement of *CES1A* in the

detoxification of reactive intermediates and carcinogens. It appears that *CES1A* is associated with lipid elimination in the liver [4–6]. Oxidative stress is one of the causal factors for hepatic steatosis, which leads to liver injury [38]. Although there were no reports about the relevance of *CES1A* to hepatic steatosis, *CES1A* may be involved in the defense of the cells against hepatic steatosis.

As shown in Fig. 4B, the transcriptional activities using the plasmid containing sequence –2365 to –1989 in the 5'-flanking region of the *CES1A1* gene were increased up to 2.0-fold by overexpression of Nrf2, and it was demonstrated that the ARE4 works as a functional Nrf2 response element in the *CES1A1* gene. Although we analyzed the transcriptional activity using plasmids containing the sequences –3207 to –1, –1531 to –1, and –833 to –1 bp in the 5'-flanking region of the *CES1A1* gene, the activity was not increased by the overexpression of Nrf2 (Fig. 4A). This result was similar to that in our previous study in which a significant increase of the transcriptional activity by Nrf2 overexpression was not observed using plasmids containing the sequences –2191 or –1408 to –7 in the 5'-flanking region of the *UGT2B7* gene [24]. It is assumed that the plasmid containing the long sequence results in a complicated conformation, which makes it difficult for Nrf2 to bind to the target ARE.




Fig. 5. Electrophoretic mobility shift assays of Nrf2 binding to ARE4 in the *CES1A1* gene. Oligonucleotide probes of *CES1A1* ARE4 labeled with ^{32}P were incubated with nuclear extracts prepared from HepG2 cells treated with $10\ \mu\text{M}$ SFN or DMSO vehicle (0.1%). The sequences of the oligonucleotides are shown in Table 1. Cold oligonucleotides were used as a competitor at 5-, 25-, and 50-fold molar excess. For supershift analyses, $2\ \mu\text{g}$ of anti-Nrf2 antibodies (α -Nrf2) or normal rabbit IgG (IgG) were preincubated with the nuclear extracts on ice for 30 min. The lower arrow indicates the position of the Nrf2-dependent shifted band, and the upper one indicates the supershifted complex by anti-Nrf2 antibodies.

EMSA and ChIP assays revealed that Nrf2 binds to the 5'-flanking region in the *CES1A1* gene (Figs. 5 and 6). In EMSA, the supershifted band was observed only with the anti-Nrf2 antibody (C-20) but not with the anti-Nrf2 antibody (H-300). This result is consistent with our previous study [24]. In ChIP assays, the




Fig. 6. ChIP assays of Nrf2 binding to the *CES1A1* gene in HepG2 cells. Schematic diagram of the *CES1A1* gene is shown at the top. ChIP assays were performed as described in Section 2. HepG2 cells were treated with $10\ \mu\text{M}$ SFN or DMSO vehicle (0.1%) for 24 h. Rabbit anti-Nrf2 antibodies (C-20 and H-300) and normal rabbit IgG were used for immunoprecipitation of protein–DNA complexes. DNA fragments amplified by PCR were analyzed on 2% agarose gel.

immunoprecipitants of SFN-treated HepG2 cells obtained with anti-Nrf2 antibody (C-20) generated PCR products for region 1 containing functional ARE, but those obtained with anti-Nrf2 antibody (H-300) or normal rabbit IgG did not. Anti-Nrf2 antibody (C-20) recognizes the C-terminal of Nrf2, whereas anti-Nrf2 antibody (H-300) recognizes the N-terminal. This difference in the recognition sites between anti-Nrf2 antibodies (C-20 and H-300) may affect the results in EMSA and the ChIP assays.

Deng et al. [39] and Wu et al. [40] reported that the cholesterol-lowering drug probucol induces HO-1 via oxidative stress. Aburaya et al. [41] reported that Nrf2 is activated by non-steroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, diclofenac, ibuprofen and aspirin. Moreover, isothiocyanates such as SFN and phenethyl isothiocyanate are found broadly distributed among cruciferous vegetables, e.g., cabbage and broccoli. It was reported that the intake of cruciferous vegetables for 2 weeks lowers serum bilirubin concentrations (from 15.73 to $14.02\ \mu\text{mol/L}$) by up-regulating UGT1A1 activity [42]. In human skin, NQO1 activity is induced up to 1.5-fold by sulforaphane-containing broccoli sprouts [43]. Because *CES1A1* is involved in the metabolism of a number of clinically used drugs and prodrugs, the combined use of drugs or dietary foods that activate Nrf2 might affect the drug response.

In conclusion, we found that Nrf2 transcriptionally activates *CES1A1* through binding to the ARE in the 5'-flanking region. This is the first study to demonstrate the molecular mechanism of the inducible regulation of human *CES1A1*.

Acknowledgement

We acknowledge Mr. Brent Bell for reviewing the manuscript.

References

- [1] Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. *Clin Pharmacokinet* 2002;41:207–24.
- [2] Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. *J Pharmacol Exp Ther* 2007;319:1477–84.
- [3] Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. *Cancer Res* 2000;60:1189–92.
- [4] Pindel EV, Kedishvili NY, Abraham TL, Brzezinski MR, Zhang J, Dean RA, et al. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. *J Biol Chem* 1997;272:14769–75.
- [5] Dolinsky VW, Gilham D, Alam M, Vance DE, Lehner R. Triacylglycerol hydrolyase: role in intracellular lipid metabolism. *Cell Mol Life Sci* 2004;61:1633–51.
- [6] Becker A, Böttcher A, Lackner KJ, Fehringer P, Notka F, Aslanidis C, et al. Purification, cloning, and expression of a human enzyme with acyl coenzyme A: cholesterol acyltransferase activity, which is identical to liver carboxylesterase. *Arterioscler Thromb* 1994;14:1346–55.
- [7] Zhao B, Natarajan R, Ghosh S. Human liver cholesteryl ester hydrolase: cloning, molecular characterization, and role in cellular cholesterol homeostasis. *Physiol Genomics* 2005;23:304–10.
- [8] Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. *Drug Metab Dispos* 2002;30:488–93.
- [9] Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Koyano N, Fujii A, et al. Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. *Drug Metab Rev* 2007;39:1–15.
- [10] Fukami T, Nakajima M, Maruichi T, Takahashi S, McLeod HL, Takamiya M, et al. Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. *Pharmacogenet Genomics* 2008;18:911–20.
- [11] Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. *Biochem J* 2003;374:337–48.
- [12] Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. *Biochem J* 2003;371:887–95.
- [13] Yueh MF, Tukey RH. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. *J Biol Chem* 2007;282:8749–58.

- [14] Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β -globin locus control region. *Proc Natl Acad Sci USA* 1994;91:9926–30.
- [15] Motohashi H, O'Connor T, Katsuoka F, Engel JD, Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. *Gene* 2002;294:1–12.
- [16] Nerland DE. The antioxidant/electrophile response element motif. *Drug Metab Rev* 2007;39:235–48.
- [17] Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun* 1997;236:313–22.
- [18] Li W, Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. *Mol Carcinog* 2009;48:91–104.
- [19] Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Watanabe N, Tsukada E, et al. Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. *Drug Metab Pharmacokinet* 2008;23:73–84.
- [20] Nishimura M, Imai T, Morioka Y, Kuribayashi S, Kamataki T, Naito S. Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. *Drug Metab Pharmacokinet* 2004;19:422–9.
- [21] Takakusa H, Masumoto H, Mitsuru A, Okazaki O, Sudo K. Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. *Drug Metab Dispos* 2008;36:816–23.
- [22] Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. *Cancer Res* 2004;64:3119–25.
- [23] Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. *Clin Cancer Res* 2003;9:4983–91.
- [24] Nakamura A, Nakajima M, Higashi E, Yamanaka H, Yokoi T. Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. *Pharmacogenet Genomics* 2008;18:709–20.
- [25] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970;227:680–5.
- [26] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248–54.
- [27] Takahashi S, Katoh M, Saitoh T, Nakajima M, Yokoi T. Allosteric kinetics of human carboxylesterase 1: species difference and interindividual variability. *J Pharm Sci* 2008;97:5434–45.
- [28] Horton RM, Cai ZL, Ho SN, Pease LR. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. *Biotechniques* 1990;8:528–35.
- [29] Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. *Drug Metab Rev* 2006;38:769–89.
- [30] Gharavi N, El-Kadi AO. tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand. *Drug Metab Dispos* 2005;33:365–72.
- [31] Anwar-Mohamed A, El-Kadi AO. Sulforaphane induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma Hepa 1c1c7 and human HepG2 cells. *Cancer Lett* 2009;275:93–101.
- [32] Marchand A, Barouki R, Garlatti M. Regulation of NAD(P)H:quinone oxidoreductase 1 gene expression by CYP1A1 activity. *Mol Pharmacol* 2004;65:1029–37.
- [33] Elbekai RH, El-Kadi AO. Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium. *Toxicol Lett* 2007;172:106–19.
- [34] Sugatani J, Mizushima K, Osabe M, Yamakawa K, Kakizaki S, Takagi H, et al. Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter. *Naunyn Schmiedeberg Arch Pharmacol* 2008;377:597–605.
- [35] Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res* 2002;62:5196–203.
- [36] Cho HY, Reddy SP, Yamamoto M, Kleeberger SR. The transcription factor NRF2 protects against pulmonary fibrosis. *FASEB J* 2004;18:1258–60.
- [37] Forkert PG, Lee RP, Reid K. Involvement of CYP2E1 and carboxylesterase enzymes in vinyl carbamate metabolism in human lung microsomes. *Drug Metab Dispos* 2001;29:258–63.
- [38] Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. *J Hepatol* 2008;48:399–406.
- [39] Deng YM, Wu BJ, Witting PK, Stocker R. Probulcol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. *Circulation* 2004;110:1855–60.
- [40] Wu BJ, Kathir K, Witting PK, Beck K, Choy K, Li C, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. *J Exp Med* 2006;203:1117–27.
- [41] Aburaya M, Tanaka K, Hoshino T, Tsutsumi S, Suzuki K, Makise M, et al. Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. *J Biol Chem* 2006;281:33422–32.
- [42] Navarro SL, Peterson S, Chen C, Makar KW, Schwarz Y, King IB, et al. Cruciferous vegetable feeding alters UGT1A1 activity: diet- and genotype-dependent changes in serum bilirubin in a controlled feeding trial. *Cancer Prev Res (Phila Pa)* 2009;2:345–52.
- [43] Dinkova-Kostova AT, Fahey JW, Wade KL, Jenkins SN, Shapiro TA, Fuchs EJ, et al. Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. *Cancer Epidemiol Biomarkers Prev* 2007;16:847–51.

Interactions Between Human UDP-Glucuronosyltransferase (UGT) 2B7 and UGT1A Enzymes

RYOICHI FUJIWARA,¹ MIKI NAKAJIMA,¹ SHINGO ODA,¹ HIROYUKI YAMANAKA,¹ SHIN-ICHI IKUSHIRO,² TOSHIYUKI SAKAKI,² TSUYOSHI YOKOI¹

¹Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

²Food Science and Technology, Biotechnology Research Center, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan

Received 16 February 2009; revised 23 April 2009; accepted 28 April 2009

Published online 27 May 2009 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.21830

ABSTRACT: Glucuronidation catalyzed by UDP-glucuronosyltransferase (UGT) enzymes is an important pathway in the metabolism of drugs as well as environmental chemicals. In this study, protein–protein interactions between human UGT2B7 and UGT1As and their effects on the enzymatic activities were investigated using double expression systems in HEK293 cells (UGT2B7/UGT1A1, UGT2B7/UGT1A4, UGT2B7/UGT1A6, and UGT2B7/UGT1A9). Native-PAGE analysis clearly revealed that UGT2B7 forms homo-oligomers. Furthermore, hetero-oligomers of UGT2B7 with UGT1As were observed by native-PAGE analysis. Immunoprecipitation assay revealed associations of UGT2B7 with UGT1A1, UGT1A4, UGT1A6, and UGT1A9. The thermal stability of UGT2B7 was significantly increased by the coexpressed UGT1A1, UGT1A4, UGT1A6, and UGT1A9, indicating an interaction between UGT2B7 and the UGT1As. To examine the effects of the protein–protein interactions on the enzymatic activities, kinetic analyses were performed. Coexpression of the UGT1As significantly decreased K_m and increased V_{max} of zidovudine *O*-glucuronidation by UGT2B7. Coexpression of UGT2B7 also affected the kinetics of estradiol 3-*O*-glucuronidation by UGT1A1, imipramine *N*-glucuronidation by UGT1A4, serotonin *O*-glucuronidation by UGT1A6, and propofol *O*-glucuronidation by UGT1A9. In conclusion, it was clearly demonstrated that human UGT2B7 interacts with UGT1A enzymes, affecting their kinetics. That such interactions might occur in human liver microsomes underscores the complexities in glucuronidations in human liver. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association *J Pharm Sci* 99:442–454, 2010

Keywords: hepatic metabolism; enzyme kinetics; phase II enzymes; glucuronosyltransferases (UGT); metabolic clearance

INTRODUCTION

UDP-Glucuronosyltransferases (UGTs) catalyze the conjugation of endogenous and exogenous

compounds with UDP-glucuronic acid (UDPGA).¹ Human UGTs are classified into three subfamilies, UGT1A, UGT2A, and UGT2B, based on evolutionary divergence.² The human *UGT1A* gene cluster located on chromosome 2q37 contains multiple unique first exons for each UGT1A, with exons 2–5 in common,³ encoding nine kinds of functional UGT1As. The *UGT2A* and *UGT2B* genes are located on chromosome 4q13, encoding three and seven functional proteins, respectively. UGT2A1 and UGT2A2 are formed by differential splicing of variable first exons and the common

Abbreviations: UGT, UDP-glucuronosyltransferase; UDPGA, UDP-glucuronic acid; HPLC, high performance liquid chromatography.

Correspondence to: Tsuyoshi Yokoi (Telephone: 81-76-234-4407; Fax: 81-76-234-4407;

E-mail: tyokoi@kenroku.kanazawa-u.ac.jp)

Journal of Pharmaceutical Sciences, Vol. 99, 442–454 (2010)

© 2009 Wiley-Liss, Inc. and the American Pharmacists Association

exons 2–6, likely the *UGT1A* gene. However, UGT2A3 and each UGT2B are encoded by individual genes. Human UGTs are expressed in a tissue-specific manner.⁴ Previous studies using reverse transcription-polymerase chain reaction (PCR) revealed that UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, and UGT2B17 are expressed in human liver.^{4–6}

Mammalian UGTs are located on the endoplasmic reticulum membrane and most of their mass is in the luminal side. That UGTs form homo- or hetero-oligomers was revealed by a variety of techniques including gel permeation chromatography,⁷ radiation inactivation analysis,^{8,9} a cross-linking study,¹⁰ SDS-PAGE,¹¹ two-hybrid analysis,¹² a heterologous expression study,^{13,14} immobilized metal-chelating chromatography,¹⁵ and fluorescence resonance energy transfer method.¹⁶ Using the heterologous expression technique, we demonstrated that human UGT1A1, UGT1A4, UGT1A6, and UGT1A9 interact with each other via heterodimerization. The heterodimerization of these UGT1A enzymes caused diverse changes of enzyme activities depending on the UGT isoforms and substrates.^{17–19} In the present study, we expanded our examination of UGT2B7, because UGT2B7 is the most important isoform for the metabolism of clinically used drugs such as morphine, zidovudine, and valproic acid²⁰ and is expressed in various tissues including liver, intestine, and kidney. Kurkela et al.²¹ has reported that coexpressed UGT1A6 decreased the activity of UGT2B7, but their interaction was not directly proven. Furthermore, there is no information on the interactions between UGT2B7 and the other human UGT1As. In this study, to understand the interactions between UGT2B7 and UGT1A enzymes, we established double expression systems of UGT2B7/UGT1A1, UGT2B7/UGT1A4, UGT2B7/UGT1A6, and UGT2B7/UGT1A9 in HEK293 cells. By native-PAGE analysis, immunoprecipitation assay, and thermal stability assay, we evaluated the significance of the interactions between UGT2B7 and UGT1A enzymes. Finally, the effects of the interactions on their enzyme activities were assessed.

MATERIALS AND METHODS

Chemicals and Reagents

UDPGA, alamethicin, estradiol, and estradiol 3-glucuronide were purchased from Sigma-Aldrich

(St. Louis, MO). Zidovudine, imipramine, serotonin, propofol, and G418 were from Wako Pure Chemicals Industries (Osaka, Japan). Zidovudine *O*-glucuronide was obtained from Toronto Research Chemicals (Toronto, Canada). Rabbit anti-human UGT1A polyclonal antibody, rabbit anti-human UGT1A1 polyclonal antibody, rabbit anti-human UGT2B7 polyclonal antibody, and human liver microsomes from 11 individuals were obtained from BD Gentest (Woburn, MA). Rabbit anti-human UGT2B polyclonal antibody (H-300) and goat anti-human UGT2B polyclonal antibody (F-17) were purchased from Santa Cruz Biotechnology (San Diego, CA). Mouse anti-KDEL monoclonal antibody was obtained from Stressgen Biotechnologies (San Diego, CA). Perfect NT Gel M was purchased from DRC (Tokyo, Japan). Primers were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). All other chemicals and solvents were of analytical grade or the highest grade commercially available.

Stable Single and Double UGT Expression Systems in HEK293 Cells

Expression vectors for human UGT1A1, UGT1A4, UGT1A6, and UGT1A9 were previously constructed.¹⁸ Human UGT2B7 (accession number NM_001074) cDNA was prepared by a reverse transcription-PCR technique from human liver total RNA with sense and antisense oligonucleotide primers (5'-ATT GCA CCA GGA TGT CTG-3' and 5'-CTT GCA TCA CAA TCT TTC TTG CTG-3'). The PCR products were subcloned into pTARGET Mammalian Expression Vector (Promega, Madison, WI) and the DNA sequences of the inserts were determined using a Thermo Sequenase Cy5.5 Dye Terminator Cycle Sequencing kit (GE Healthcare Bio-Science, Piscataway, NJ) with a Long-Read Tower DNA sequencer (GE Healthcare Bio-Science). HEK293 cells (American Type Culture Collection, Manassas, VA) were grown in Dulbecco's modified Eagle's medium containing 4.5 g/L glucose, 10 mM HEPES, and 10% fetal bovine serum with 5% CO₂ at 37°C. Two micrograms of the UGT expression vector were transfected into HEK293 cells in 6-well plates with Lipofectamine (Invitrogen, Carlsbad, CA). For the double expression systems, the expression vector for UGT2B7 was simultaneously transfected into the cells with each UGT1A expression vector (UGT1A1, UGT1A4, UGT1A6, or UGT1A9) at the ratio of 1:1. Stable transfectants were

selected in medium containing 800 $\mu\text{g}/\text{mL}$ G418 and several clones were isolated.

SDS-PAGE or Native-PAGE and Immunoblot Analysis

To determine the expression levels of UGT2B7 and UGT1As in the constructed recombinant systems, SDS-PAGE and immunoblot analysis were performed using anti-UGT2B and anti-UGT1A antibodies and an Odyssey infrared imaging system (Li-COR Biosciences, Lincoln, NE). Since the titer of the rabbit anti-UGT2B antibody was higher than that of the rabbit anti-UGT2B7 antibody, the rabbit anti-UGT2B antibody was used. Although it was confirmed that UGT enzymes are expressed in microsomes fraction, total cell homogenates prepared as described previously¹⁸ were used for convenience in this study. The total cell homogenates (10 μg of protein) were subjected to 10% SDS-PAGE and transferred to a PVDF membrane Immobilon-P (Millipore, Bedford, MA). The membrane was washed with phosphate buffered saline (PBS) two times and blocked with Odyssey Blocking Buffer (Li-COR Biosciences) for 1 h. The membrane was probed with the primary antibody diluted (1:500) with Odyssey Blocking Buffer containing 0.1% Tween-20 for 1 h. The membrane was washed with PBST (PBS containing 0.1% Tween-20) four times and incubated with IRDye680-labeled goat anti-rabbit secondary antibody diluted (1:5000) with PBST for 1 h. The densities of the bands were determined using the Odyssey infrared imaging system. Although the expression levels of UGT2B7 and UGT1As cannot be simply compared because the primary antibodies are different, the relative expression levels of UGT2B7 and UGT1A1 were defined based on standard curves using their single expression systems (1 U/1 mg of cell homogenates) for convenience.

To determine the expression levels of UGT2B7 and UGT1A1 proteins in human liver microsomes, SDS-PAGE and immunoblot analysis were performed using anti-UGT2B7 and anti-UGT1A1 antibodies. For the quantification, the UGT2B7 and UGT1A1 single expression systems were used to make the standard curves as described above.

Native-PAGE analysis was performed to detect monomer and oligomer formations of UGTs as described previously¹⁷ with slight modifications. Ten to 100 μg of total cell homogenates were lysed in solubilizing buffer (0.5% NP-40, 0.25% sodium

deoxycholate, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 1 mM EDTA) on ice for 2 h. After centrifugation at 13,000g for 30 min, 1 μL of 60% glycerol containing 0.2% bromophenol blue was added to a 20- μL portion of the supernatant. The samples were applied to Perfect NT Gel M (5–20% gradient) and the electrophoresis was carried out at 10 mA for 5 h at 4°C in Tris-glycine electrophoresis buffer (25 mM Tris-base, 192 mM glycine, and 0.1% SDS). The separated proteins were transferred to a PVDF membrane and probed with the anti-UGT2B and anti-UGT1A antibodies as described above.

Immunoprecipitation

Rabbit anti-human UGT1A antibody (BD Gentest) or rabbit anti-human UGT1AC antibody²² against common carboxyl-terminal region of UGT1A was cross-linked with protein-Sepharose CL-4B (GE Healthcare Bio-Sciences) as described previously.¹⁸ The beads were resuspended in solubilizing buffer (0.5% NP-40, 0.25% deoxycholate, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA). Cell homogenates (500 μg) were solubilized with the solubilizing buffer in a final concentration of 1.0 mg/mL at 4°C for 2 h. After centrifugation at 13,000g for 30 min at 4°C, the supernatants were incubated with the beads at 4°C for 14 h. The beads were washed three times with the solubilizing buffer. The bound proteins were eluted with 2M guanidine hydrochloride for 6 h at room temperature. The eluates were subjected to SDS-PAGE followed by immunoblot analysis with anti-UGT1A, rabbit or goat anti-UGT2B, and anti-KDEL antibodies.

Glucuronide Formation

Zidovudine *O*-glucuronide formation was determined according to a method by Court et al.²³ with slight modifications. A typical incubation mixture (200 μL total volume) contained 50 mM phosphate buffer (pH 7.4), 5 mM MgCl_2 , 5 mM UDPGA, 0.2 mg/mL total cell homogenates, alamethicin (50 $\mu\text{g}/\text{mg}$ of protein), and 0.25–1.2 mM zidovudine. The reaction was initiated by the addition of UDPGA following a 2 min preincubation at 37°C. The incubation mixture was incubated at 37°C for 60 min, since it was confirmed that the zidovudine *O*-glucuronide formation was linear over 90 min. After the incubation, the reaction was terminated by the addition of 10 μL of 30% perchloric acid.

The reaction mixture was centrifuged at 7,000g for 10 min, and 60 μ L of the supernatant was subjected to HPLC. The analytical column was an Inertsil ODS-3 (4.6 mm \times 250 mm; 5 μ m) (GL Sciences, Tokyo, Japan). The mobile phase was 10% acetonitrile/10 mM potassium phosphate buffer (pH 2.3) and the flow rate was 1.0 mL/min. The column eluate was monitored at 267 nm. The retention times of zidovudine *O*-glucuronide and zidovudine were 10.4 and 15.0 min, respectively. The quantification of zidovudine *O*-glucuronide was made by comparing the HPLC peak height to that of the authentic standard.

For the study of thermal stability, reaction mixtures containing the cell homogenate were treated at 47°C for 15 min in the presence of UDPGA. Then, zidovudine was added to the mixture at a final concentration of 250 μ M and the mixture was incubated at 37°C for 60 min to determine the residual enzyme activity.

Estradiol 3-*O*-glucuronide formation, imipramine *N*-glucuronide formation, serotonin *O*-glucuronide formation, and propofol *O*-glucuronide formation were determined as described previously.¹⁸

Kinetic parameters were estimated from the fitted curve using a computer program (Kaleida-Graph, Synergy Software, Reading, PA) designed for nonlinear regression analysis. The following equations were used:

Michaelis–Menten equation

$$V = \frac{V_{\max}[S]}{K_m + [S]}$$

Hill equation

$$V = \frac{V_{\max}[S]^n}{S_{50}^n + [S]^n}$$

Substrate inhibition equation

$$V = \frac{V_{\max}[S]}{K_m + [S] + [S]^2/K_i}$$

where V is the velocity of the reaction, S the substrate concentration, K_m the Michaelis–Menten constant, V_{\max} the maximum velocity, S_{50} the substrate concentration showing the half V_{\max} , n the Hill coefficient, and K_i the substrate inhibition constant. For the Michaelis–Menten kinetics and the substrate inhibition kinetics, the intrinsic clearance (CL_{int}) was calculated as the V_{\max}/K_m . For sigmoidal kinetic data, the maximum clearance (CL_{max}), which has been proposed

as an appropriate parameter instead of the intrinsic clearance,^{24,25} was calculated by the following equation:

$$CL_{\text{max}} = \frac{V_{\max}}{S_{50}} \frac{(n-1)}{n(n-1)^{1/n}}$$

Statistical Analyses

Data are expressed as mean \pm SD of three independent determinations. The statistical significance of the kinetic parameters was determined by analysis of variance (ANOVA) followed by Dunnett's test. A value of $P < 0.05$ was considered statistically significant.

RESULTS

Establishment of Single and Double Expression Systems of UGT2B7 and UGT1As in HEK293 Cells

To investigate whether human UGT2B7 interacts with UGT1A enzymes, stable single expression systems (UGT2B7, UGT1A1, UGT1A4, UGT1A6, and UGT1A9) and double expression systems (UGT2B7/UGT1A1, UGT2B7/UGT1A4, UGT2B7/UGT1A6, and UGT2B7/UGT1A9) in HEK293 cells were constructed. The expression levels of UGT protein were determined by immunoblot analysis (Fig. 1A). The expression levels of UGT2B7 and UGT1A1 in the single expression system were defined as 1.00 U/mg. Based on the expression level of UGT1A1 in the single expression system, the UGT1A4, UGT1A6, and UGT1A9 levels in single expression systems were estimated as 0.18, 0.13, and 0.35 U/mg protein, respectively. In two clones of the double expression system for UGT2B7/UGT1A1, the expression levels of UGT2B7 (0.10 and 0.14 U/mg) and UGT1A1 (0.51 and 0.12 U/mg) resulted in a 2B7/1A ratio 0.2 and 1.2. In two clones of the double expression system for UGT2B7/UGT1A4, the expression levels of UGT2B7 (0.12 and 0.27 U/mg) and UGT1A4 (0.79 and 0.24 U/mg) resulted in a 2B7/1A ratio 0.2 and 1.1. In two clones of the double expression system for UGT2B7/UGT1A6, the expression levels of UGT2B7 (0.22 and 0.12 U/mg) and UGT1A6 (0.57 and 0.09 U/mg) resulted in a 2B7/1A ratio 0.4 and 1.3. In two clones of the double expression system for UGT2B7/UGT1A9, the expression levels of UGT2B7 (0.10 and 0.19 U/mg) and UGT1A9 (0.22 and 0.07 U/mg) resulted in a 2B7/1A ratio 0.5 and 2.7.




Figure 1. Immunoblot analysis of human UGT2B7 and UGT1As in the single and double expression systems as well as human liver microsomes. The total cell homogenates from the HEK293 expression systems (10 μg protein) were subjected to 10% SDS-PAGE and the membranes were probed with the anti-human UGT2B and anti-human UGT1A antibodies (A). For the analysis of UGT2B7 and UGT1A1 in human liver microsomes, 5- and 2-μg protein of human liver microsomes, respectively, were applied and the membranes were probed with anti-human UGT2B7 and anti-human UGT1A1 antibodies (B). The rightmost lane in the membranes shows the UGT2B7 single expression system (5 μg protein) and the UGT1A1 single expression system (2 μg protein). The expression levels of UGT2B7 and UGT1As were defined based on standard curves using the UGT2B7 and UGT1A1 single expression systems (1 U/1 mg of cell homogenates). Columns are the mean ± SD of three independent determinations.

Expression Levels of UGT1A1 and UGT2B7 Proteins in Human Liver Microsomes

To investigate how similar the UGT2B7/UGT1A ratios in our expression systems were to those in human liver microsomes, we determined the expression levels of UGT2B7 and UGT1A1 protein in human liver microsomes by immunoblot analyses. Since human liver microsomes express multiple UGT isoforms, the specific antibodies against UGT2B7 or UGT1A1 were used. The

expression levels were quantified using standard curves of the UGT2B7 and UGT1A1 single expression systems in HEK293 cells. The expression level of UGT2B7 and UGT1A1 proteins in 11 individual human liver microsomes ranged from 0.49 to 1.53 and 1.36 to 4.20 U/mg of protein, respectively (Fig. 1B). The UGT2B7/UGT1A1 ratios ranged from 0.2 to 0.9. These results suggest that the ratios of UGT2B7/UGT1A in our expression systems were similar to the ratios of UGT2B7/UGT1A1 in human liver microsomes.

Native-PAGE Analysis of Single and Double Expression Systems

Native-PAGE analysis was performed to investigate the oligomerizations of human UGT2B7 and UGT1As. First, we confirmed that UGT enzymes were efficiently solubilized with the solubilizing buffer (data not shown). When the total cell homogenate of the single expression system of UGT2B7 was separated, three bands were observed at about 50, 100, and 130 kDa (Fig. 2, arrows 1–3, respectively). These three bands were also observed in the double expression systems of UGT2B7 and UGT1As, but not in Mock cells and the single expression systems of UGT1As. The lower (arrow 1) and middle (arrow 2) bands would correspond to monomers and homodimers, respectively. The upper band (arrow 3) might be an oligomeric form of UGT2B7 that is greater than the dimer. In our previous study,¹⁷ when the double expression system of UGT1A1/UGT1A4 was applied for the native-PAGE analysis, a unique band corresponding to a heterodimer was observed. Interestingly, several bands were detected at around 150–250 kDa in the double expression of UGT2B7 and UGT1As, but not in the single expression system of UGT2B7. Therefore, these unique bands might represent hetero-oligomers of UGT2B7 and UGT1As. To further




Figure 2. Native-PAGE analyses of UGT2B7 and UGT1As in the single and double expression systems. As the double expression systems, the 2B7/1A1-2, 2B7/1A4-2, 2B7/1A6-2, and 2B7/1A9-2 clones were used. Solubilized total cell homogenates were subjected to gradient gel (5–20%). After electrophoresis at 4°C, the proteins were transferred to a PVDF membrane and immunoblotted with rabbit anti-human UGT2B antibody. Arrows 1–3 represent the bands corresponding to monomer, homodimer, and homo-oligomers of UGT2B7, respectively.

investigate the hetero-oligomerizations between UGT2B7 and UGT1As, coimmunoprecipitation and thermal stability assay were performed.

Coimmunoprecipitation of UGT2B7 with Anti-Human UGT1A Antibody

To investigate the association between UGT2B7 and the UGT1A enzymes, immunoprecipitation analysis was carried out using anti-human UGT1A antibody (Fig. 3A). Using the single expression systems, it was confirmed that the anti-human UGT1A antibody specifically immunoprecipitated the UGT1As. When the double expression systems were used, UGT2B7 protein was coimmunoprecipitated by the anti-human UGT1A antibody, although the band density of the UGT2B7 from the double expression system for UGT2B7/1A1 was weaker than those of the other double expression systems. Glucose-regulated protein 94 (GRP94) and GRP78 that are expressed in endoplasmic reticulum were not detected in the immunoprecipitants, indicating the specific interaction between UGT2B7 and the UGT1As. When the anti-human UGT1AC antibody was used for immunoprecipitation, UGT2B7 protein was coimmunoprecipitated from the double expression systems (Fig. 3B). Especially, the band density from the double expression systems for UGT2B7/1A4 and UGT2B7/UGT1A9 was substantial. It was confirmed that UGT1As were immunoprecipitated by the anti-human UGT1AC antibody, and that GRP94 and GRP78 were not detected in the immunoprecipitants. The results suggest that UGT2B7 specifically interacts with the UGT1A enzymes.

Effects of Coexpression of UGT1A on Thermal Instability of UGT2B7

Thermal instability is a useful tool for analyzing protein–protein interactions.¹⁸ As a specific activity for UGT2B7, zidovudine *O*-glucuronidation was measured, since we confirmed that UGT1A1, UGT1A4, UGT1A6, and UGT1A9 could not catalyze this reaction (data not shown). The enzymatic activities in the single and double expression systems were normalized with the UGT2B7 protein levels by immunoblot analysis. Zidovudine *O*-glucuronide formation by the UGT2B7 single expression system was decreased to 5% of control by heat treatment at 47°C for 15 min (Fig. 4), indicating that UGT2B7 is thermally




Figure 3. Coimmunoprecipitation of UGT2B7 by anti-human UGT1A antibody using the double expression systems of UGT2B7/UGT1As. Rabbit anti-human UGT1A antibody from BD Gentest (A) or rabbit anti-human UGT1AC antibody prepared by Ikushiro et al.²² (B) were used for immunoprecipitation. The input proteins and coimmunoprecipitants were subjected to SDS-PAGE followed by immunoblot analysis using anti-human UGT1A, anti-human UGT2B. Anti-KDEL antibodies detected GRP94 and GRP78 only in the input proteins.

instable. UGT2B7 in the double expression systems of UGT2B7/UGT1As showed tolerability to the heat treatment. The results suggest that UGT2B7 interacted with UGT1A1, UGT1A4, UGT1A6, and UGT1A9 in the double expression systems.

Kinetic Analyses of Zidovudine, Estradiol, Imipramine, Serotonin, and Propofol Glucuronide Formations

To investigate the effects of the coexpression of UGT1A enzymes on the enzymatic activity of UGT2B7, kinetic analysis of zidovudine *O*-glucuronide formation was carried out using the single and double expression systems. It was confirmed that any UGT1A enzymes did not show a

detectable zidovudine *O*-glucuronide formation (data not shown). The zidovudine *O*-glucuronide formation by the single expression system of UGT2B7 in HEK293 cells fitted to the Michaelis-Menten kinetics (Fig. 5A) with $K_m = 282 \pm 16 \mu\text{M}$, $V_{\max} = 449 \pm 16 \text{ pmol/min/U}$, and $CL_{\text{int}} = 1.6 \pm 0.1 \mu\text{L/min/U}$ (Tab. 1). The kinetic parameters were reproducible in another clone of the UGT2B7 single expression system (data not shown). By the coexpression of UGT1A1, the V_{\max} and CL_{int} values were significantly increased (Fig. 5A and Tab. 1). By the coexpression of UGT1A4, the K_m value was significantly decreased and the V_{\max} and CL_{int} values were significantly increased compared with those values in the UGT2B7 single expression system (Fig. 5B and Tab. 1). A significant decrease of K_m and increases of the V_{\max} and CL_{int} values were also observed in the




Figure 4. Effect of heat treatment on the enzymatic activities of UGT2B7 in the single and double expression systems. After the preincubation of the total cell homogenates at 47°C for 15 min in the presence of UDPGA, zidovudine *O*-glucuronide formation was measured with 250 μ M of substrate. Each column shows the residual activity after the heat treatment. Data are the mean \pm SD of three independent determinations. * $P < 0.05$ and ** $P < 0.01$ compared with the UGT2B7 single expression system.

double expression systems with UGT1A6 and UGT1A9 (Fig. 5C and D and Tab. 1).

The effects of the coexpression of UGT2B7 on the enzymatic activities of UGT1A1, UGT1A4, UGT1A6, and UGT1A9 were investigated. It was confirmed that the estradiol 3-*O*-glucuronide, imipramine *N*-glucuronide, serotonin *O*-glucuronide, and propofol *O*-glucuronide formations were specifically catalyzed by UGT1A1, UGT1A4, UGT1A6, and UGT1A9, respectively (data not shown). The estradiol 3-*O*-glucuronide formation by the single expression system of UGT1A1 in HEK293 cells followed the Hill equation (Fig. 5E), yielding $S_{50} = 17.5 \pm 3.3 \mu\text{M}$, $V_{\text{max}} = 0.8 \pm 0.0 \text{ nmol/min/U}$, Hill coefficient (n) = 1.4 ± 0.2 , and $\text{CL}_{\text{max}} = 27.0 \pm 2.8 \mu\text{L/min/U}$ (Tab. 2). These kinetic parameters were consistent with those of our previous study.¹⁸ By the coexpression of UGT2B7, the S_{50} was significantly decreased and the n value and CL_{max} values were significantly increased (Tab. 2). The imipramine *N*-glucuronide formation by the single expression system of UGT1A4 in HEK293 cells showed substrate inhibition at substrate concentrations $>1.5 \text{ mM}$ (Fig. 5F). When the kinetics were analyzed by fitting to the Michaelis–Menten kinetics with substrate concentrations up to 1.0 mM, the K_m , V_{max} , and

CL_{int} values were $0.6 \pm 0.03 \text{ mM}$, $1.4 \pm 0.1 \text{ nmol/min/U}$, and $2.3 \pm 0.1 \mu\text{L/min/U}$, respectively (Tab. 2). By the coexpression of UGT2B7, the K_m and V_{max} values were significantly increased. The serotonin *O*-glucuronide formation by the single expression system of UGT1A6 fitted to the Michaelis–Menten kinetics (Fig. 5G) with $K_m = 7.6 \pm 2.0 \text{ mM}$, $V_{\text{max}} = 2.7 \pm 0.7 \text{ nmol/min/U}$, and $\text{CL}_{\text{int}} = 0.4 \pm 0.1 \mu\text{L/min/U}$ (Tab. 2). By the coexpression of UGT2B7, the V_{max} and CL_{int} values were increased. The propofol *O*-glucuronide formation by the single expression system of UGT1A9 fitted to the substrate inhibition kinetics (Fig. 5H) with $K_m = 67.7 \pm 5.2 \mu\text{M}$, $V_{\text{max}} = 43.7 \pm 3.7 \text{ nmol/min/U}$, $K_i = 1.0 \pm 0.1 \text{ mM}$, and $\text{CL}_{\text{int}} = 0.7 \pm 0.0 \mu\text{L/min/U}$ (Tab. 2). The V_{max} and CL_{int} values in the clone 2B7/1A9-1 were significantly increased. These results suggest that UGT2B7 affected the UGT1A1, UGT1A4, UGT1A6, and UGT1A9 activity, and *vice versa*. It was confirmed that mixing of each single expression system did not influence the kinetics of the enzymatic activities (data not shown). Taken together, it is suggested that the coexpressed UGT isoforms functionally interacted with each other in the double expression systems.

DISCUSSION

Accumulating evidence has revealed that UGTs form oligomers.²⁶ Our previous studies demonstrated that human UGT1A enzymes interact each other via heterodimerization, resulting in changes of the enzymatic properties.^{17–19} We expanded our study to investigate whether UGT2B7, one of the major UGT isoforms expressed in human liver, interacts with UGT1As, and to determine the effects of the interaction on the enzymatic activities.

The homo-oligomerizations of human UGT1A enzymes has been demonstrated,^{15,16} but it has never been determined whether human UGT2B7 forms homo-oligomers. Previously, we reported that native-PAGE analysis is a useful technique to detect oligomers¹⁷ and we could show the homo-dimerization of UGT1A1, UGT1A4, and UGT1A6. In the present study, the native-PAGE analysis clearly demonstrated the homo-oligomerizations of UGT2B7 (Fig. 2). The results suggested the possibility that UGT2B7 may have the ability to form hetero-oligomer with UGT1A enzymes. Interestingly, bands of hetero-oligomers were also